Immunic Appoints New Director, Finalizes Founder/Former CEO Separation with Substantial Severance and Full Equity Vesting
IMUX has more than doubled off its 52-week low of $5.062.
Summary
Immunic appointed a new director with strong financial expertise and finalized the separation of its founder and former CEO, including a substantial cash severance and full equity vesting.
Key Events · Executive and Board Changes · IMUX
-
Q2 2026 Financial Results Announced
The company reported a cash position of $155.1 million as of June 30, 2026, which is expected to fund operations into late 2027. Net loss for Q2 2026 was $34.1 million.
-
New Director Appointed to Board
Elena Ridloff, a CFA and former CFO of Sionna Therapeutics and ACADIA Pharmaceuticals, was appointed to the Board of Directors, effective August 6, 2026. She received an inaugural grant of options to purchase 50,740 shares.
-
Founder/Former CEO Resigns from Board
Dr. Daniel Vitt resigned as a member of the Board, effective August 6, 2026. This follows his earlier resignation as CEO, effective June 1, 2026. The company stated the resignation was not due to any disagreement.
-
Substantial Severance Package for Departing Executive
Dr. Vitt entered into a separation agreement on August 7, 2026, receiving over $1.1 million in cash severance (including salary and bonus), healthcare reimbursement, and legal fees. Additionally, 100% of his outstanding equity awards vested immediately.
Analysis · IMUX · Life Sciences
This filing details significant leadership changes and financial outcomes. The appointment of Elena Ridloff, a seasoned financial executive, strengthens the board. Concurrently, the company finalized the separation of its founder and former CEO, Dr. Daniel Vitt, with a comprehensive severance package exceeding $1.1 million in cash and the immediate vesting of all his outstanding equity awards. This marks a complete transition in leadership and carries a notable financial impact for the company.
At the time of this filing, IMUX was trading at $14.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.1M. The 52-week trading range was $5.06 to $15.84. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.